NCT03296527已完成3 期
A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Pan-Asian Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing Assisted Reproductive Technology Programme
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,011
- 试验地点
- 26
- 主要终点
- Ongoing Pregnancy Rate
研究概览
简要总结
To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Informed Consent Documents signed prior to screening evaluations.
- •In good physical and mental health in the judgement of the investigator.
- •Asian pre-menopausal females between the ages of 20 and 40 years. The participants must be at least 20 years (including the 20th birthday) when they sign the informed consent and no more than 40 years (up to the day before the 41st birthday) at the time of randomization.
- •Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II (defined by the revised American Society for Reproductive Medicine [ASRM] classification, 1996) or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
- •Infertility for at least one year before randomization for participants <35 years or for at least 6 months for participants ≥35 years (not applicable in case of tubal or severe male factor infertility).
- •The trial cycle will be the participant's first controlled ovarian stimulation cycle for IVF/ICSI.
- •Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
- •Hysterosalpingography, hysteroscopy, saline infusion sonography, or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g. no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are associated with a reduced chance of pregnancy) within 1 year prior to randomization.
- •Transvaginal ultrasound documenting presence and adequate visualisation of both ovaries, without evidence of significant abnormality (e.g. enlarged ovaries which would contraindicate the use of gonadotropins) and normal adnexa (e.g. no hydrosalpinx) within 1 year prior to randomization. Both ovaries must be accessible for oocyte retrieval.
- •Early follicular phase (cycle day 2-4) serum levels of FSH between 1 and 15 IU/L (results obtained within 3 months prior to randomization).
- •Negative serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) antibody tests within 2 years prior to randomization.
- •Body mass index (BMI) between 17.5 and 32.0 kg/m2 (both inclusive) at screening.
- •Willing to accept transfer of 1-2 embryos.
排除标准
- •Known endometriosis stage III-IV (defined by the revised ASRM classification, 1996).
- •One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound prior to randomization on stimulation day 1 (puncture of cysts is allowed prior to randomization).
- •Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy (excl. ectopic pregnancy) and before week 24 of pregnancy).
- •Known abnormal karyotype of participant or of her partner / sperm donor, as applicable, depending on source of sperm used for insemination in this trial.
- •Any known clinically significant systemic disease (e.g. insulin-dependent diabetes).
- •Known inherited or acquired thrombophilia disease.
- •Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
- •Known porphyria.
- •Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) with the exception of controlled thyroid function disease.
- •Known presence of anti-FSH antibodies (based on the information available in the participant's medical records; i.e. not based on the anti-FSH antibody analyses conducted in the trial).
- •Known tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins.
- •Known moderate or severe impairment of renal or hepatic function.
- •Any abnormal finding of clinical chemistry, haematology or vital signs at screening which is clinically significant as judged by the investigator.
- •Currently breast-feeding.
- •Undiagnosed vaginal bleeding.
- •Known abnormal cervical cytology of clinical significance observed within three years prior to randomization (unless the clinical significance has been resolved).
- •Findings at the gynaecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device.
- •Pregnancy (negative urinary pregnancy tests must be documented at screening and prior to randomization) or contraindication to pregnancy.
- •Known current active pelvic inflammatory disease.
- •Use of fertility modifiers during the last menstrual cycle before randomization, including dehydroepiandrosterone (DHEA), metformin or cycle programming with oral contraceptives, progestogen or estrogen preparations.
- •Use of hormonal preparations (except for thyroid medication) during the last menstrual cycle before randomization.
- •Known history of chemotherapy (except for gestational conditions) or radiotherapy.
- •Current or past (1 year prior to randomization) abuse of alcohol or drugs.
- •Current (last month) intake of more than 14 units of alcohol per week.
- •Current or past (3 months prior to randomization) smoking habit of more than 10 cigarettes per day.
- •Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial.
- •Previous participation in the trial.
- •Use of any non-registered investigational drugs during the last 3 months prior to randomization.
研究组 & 干预措施
Follitropin delta
Experimental
Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
干预措施: Follitropin delta (Drug)
Gonal-F
Active Comparator
rFSH. Follitropin alfa for subcutaneous injection
干预措施: Follitropin alfa (Drug)
结局指标
主要结局
Ongoing Pregnancy Rate
时间窗: 10-11 weeks after transfer
Defined as at least one intrauterine viable fetus 10-11 weeks after transfer.
次要结局
- Number of Participants With Adverse Events(From screening up to end-of-trial (up to approximately 5.5 months))
- Ongoing Implantation Rate(10-11 weeks after transfer)
- Implantation Rate(5-6 weeks after transfer)
- Positive Beta Unit of Human Chorionic Gonadotropin (βhCG) Rate(13-15 days after transfer)
- Proportion of Subjects With Extreme Ovarian Responses(Oocyte retrieval visit)
- Number of Follicles on Stimulation Day 6(On stimulation Day 6)
- Number of Follicles At End-of-stimulation (up to 20 Stimulation Days)(At end-of-stimulation (up to 20 stimulation days))
- Size of Follicles on Stimulation Day 6(On stimulation Day 6)
- Clinical Pregnancy Rate(5-6 weeks after transfer)
- Vital Pregnancy Rate(5-6 weeks after transfer)
- Percentage of Metaphase II (MII) Oocytes(Prior to insemination)
- Fertilization Rate(On Day 1 after oocyte retrieval)
- Circulating Concentrations of Follicle-stimulating Hormone (FSH)(On stimulation Day 6)
- Total Gonadotropin Dose(Up to 20 stimulation days)
- Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS(Up to 9 days after triggering of final follicular maturation)
- Number of Oocytes Retrieved(On the day of oocyte retrieval (36 h [±2h] after triggering of final follicular maturation))
- Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved(On the day of oocyte retrieval)
- Proportion of Subjects With Cycle Cancellation Due to Poor or Excessive Ovarian Response or Embryo Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk(End-of-stimulation visit (up to 20 days) or transfer visit)
- Size of Follicles At End-of-stimulation (up to 20 Stimulation Days)(At end-of-stimulation (up to 20 stimulation days))
- Circulating Concentrations of Estradiol(End-of-stimulation (up to 20 stimulation days))
- Circulating Concentrations of Inhibin B(End-of-stimulation (up to 20 stimulation days))
- Proportion of Subjects With Investigator-requested Gonadotropin Dose Adjustments(Up to 20 stimulation days)
- Change From Baseline in Haematology Parameter: Haemoglobin(From screening up to end-of-trial (approximately 5.5 months))
- Number and Quality of Embryos(On Day 3 after oocyte retrieval)
- Circulating Concentrations of Luteinizing Hormone (LH)(On stimulation Day 6)
- Circulating Concentrations of Inhibin A(End-of-stimulation (up to 20 stimulation days))
- Circulating Concentrations of FSH(At oocyte retrieval)
- Number of Stimulation Days(Up to 20 stimulation days)
- Changes From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase(From screening up to end-of-trial (up to approximately 5.5 months))
- Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein(From screening up to end-of-trial (approximately 5.5 months))
- Change From Baseline in Clinical Chemistry Parameter: Lactate Dehydrogenase(From screening up to end-of-trial (approximately 5.5 months))
- Proportion of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralizing Capacity(Up to 28 days after end of the stimulation period)
- Proportion of Subjects With Cycle Cancellations Due to an Adverse Event, Including Immune-related Adverse Events, or Due to Technical Malfunctions of the Administration Pen(Up to 20 stimulation days)
- Proportion of Participants With Early Pregnancy Losses(End-of-trial)
- Proportion of Participants With Technical Malfunctions of the Administration Pen(End-of-stimulation (up to 20 stimulation days))
- Circulating Concentrations of LH(End-of-stimulation (up to 20 stimulation days))
- Intensity of Adverse Events(From screening up to end-of-trial (up to approximately 5.5 months))
- Change From Baseline in Clinical Chemistry Parameters: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium(From screening up to end-of-trial (approximately 5.5 months))
- Proportion of Subjects With Markedly Abnormal Changes of Clinical Chemistry: Alanine Aminotransferase, Aspartate Aminotransferase, Bicarbonate, Calcium, Phosphate(End-of-stimulation visit and end-of-trial visit)
- Change From Baseline in Haematology Parameter: Erythrocytes(From screening up to end-of-trial (approximately 5.5 months))
- Change From Baseline in Haematology Parameter: Erythrocyte Mean Corpuscular Haemoglobin Concentration(From screening up to end-of-trial (approximately 5.5 months))
- Change From Baseline in Haematology Parameters: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes(From screening up to end-of-trial (approximately 5.5 months))
- Number of Immune-related Adverse Events(From screening up to end-of-trial (approximately 5.5 months))
- Intensity of Injection Site Reactions(End-of-stimulation (up to 20 stimulation days))
- Intensity of Immune-related Adverse Events(From screening up to end-of-trial (approximately 5.5 months))
- Proportion of Participants With Multi-fetal Gestation(End-of-trial)
- Circulating Concentrations of Progesterone(End-of-stimulation (up to 20 stimulation days))
- Change From Baseline in Haematology Parameter: Erythrocyte Mean Corpuscular Volume(From screening up to end-of-trial (approximately 5.5 months))
- Change From Baseline in Haematology Parameter: Erythrocyte Mean Corpuscular Haemoglobin(From screening up to end-of-trial (approximately 5.5 months))
- Proportion of Subjects With Markedly Abnormal Changes of Haematology Parameters: Leukocytes, Lymphocytes/Leukocytes(End-of-stimulation visit and end-of-trial visit)
- Change From Baseline in Haematology Parameters: Leukocytes and Platelets(From screening up to end-of-trial (approximately 5.5 months))
- Change From Baseline in Clinical Chemistry Parameter: Direct Bilirubin, Bilirubin, Creatinine, Urate(From screening up to end-of-trial (approximately 5.5 months))
- Change From Baseline in Haematology Parameter: Haematocrit(From screening up to end-of-trial (approximately 5.5 months))
- Frequency of Injection Site Reactions(End-of-stimulation (up to 20 stimulation days))
- Proportion of Subjects With Late OHSS(After 9 days post triggering of final follicular maturation)
研究者
研究点 (26)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian WomenInfertilityNCT04773353Ferring Pharmaceuticals220
已完成
3 期
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1InfertilityNCT01956110Ferring Pharmaceuticals1,329
已完成
3 期
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese WomenInfertilityNCT03228680Ferring Pharmaceuticals373
已完成
2 期
A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI TreatmentInfertilityNCT01426386Ferring Pharmaceuticals265
已完成
3 期
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)InfertilityNCT03740737Ferring Pharmaceuticals579